Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 10/2016

Open Access 01-09-2016 | Review Article

Highlights lecture EANM 2015: the search for nuclear medicine’s superheroes

Authors: Andreas Buck, Clemens Decristoforo

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 10/2016

Login to get access

Abstract

The EANM 2015 Annual Congress, held from October 10th to 14th in Hamburg, Germany, was outstanding in many respects. With 5550 participants, this was by far the largest European congress concerning nuclear medicine. More than 1750 scientific presentations were submitted, with more than 250 abstracts from young scientists, indicating that the future success of our discipline is fuelled by a high number of young individuals becoming involved in a multitude of scientific activities. Significant improvements have been made in molecular imaging of cancer, particularly in prostate cancer. PSMA-directed PET/CT appears to become a new gold standard for staging and restaging purposes. Novel tumour specific compounds have shown their potential for target identification also in other solid neoplasms and further our understanding of tumour biology and heterogeneity. In addition, a variety of nuclear imaging techniques guiding surgical interventions have been introduced. A particular focus of the congress was put on targeted, radionuclide based therapies. Novel theranostic concepts addressing also tumour entities with high incidence rates such as prostate cancer, melanoma, and lymphoma, have shown effective anti-tumour activity. Strategies have been presented to improve further already established therapeutic regimens such as somatostatin receptor based radio receptor therapy for treating advanced neuroendocrine tumours. Significant contributions were presented also in the neurosciences track. An increasing number of target structures of high interest in neurology and psychiatry are now available for PET and SPECT imaging, facilitating specific imaging of different subtypes of dementia and movement disorders as well as neuroinflammation. Major contributions in the cardiovascular track focused on further optimization of cardiac perfusion imaging by reducing radiation exposure, reducing scanning time, and improving motion correction. Besides coronary artery disease, many contributions focused on cardiac inflammation, cardiac sarcoidosis, and specific imaging of large vessel vasculitis. The physics and instrumentation track included many highlights such as novel, high resolution scanners. The most noteworthy news and developments of this meeting were summarized in the highlights lecture. Only 55 scientific contributions were mentioned, and hence they represent only a brief summary, which is outlined in this article. For a more detailed view, all presentations can be accessed by the online version of the European Journal of Nuclear Medicine and Molecular Imaging (Volume 42, Supplement 1).
Literature
1.
Gillebert Q, Huchet V, Rousseau C, Cochet A, Olivier P, Courbon F, et al. Usefulness of 18F-fluorocholine positron emission tomography-computed tomography inoccult biochemical recurrence of prostate cancer. A prospective multicentre study. Eur J Nucl Med Mol Imaging. 2015;42 Suppl 1:S106.
2.
Morigi J, Stricker P, van Leeuwen P, Tang R, Ho B, Nguyen Q, et al. Prospective comparison of the detection rate of 18F-Fluoromethylcholine and 68Ga-PSMA-HBED PET/CT in men with prostate cancer with rising PSA post curative intent therapy, being considered for targeted therapy. Eur J Nucl Med Mol Imaging. 2015;42 Suppl 1:S35.
3.
Zanoni L, Schiavina R, Pultrone C, Pettinato C, Fonti C, Semini S, et al. 18F-FACBC PET/CT for the detection of recurrence in patients radically treated for prostate cancer with biochemical relapse: preliminary accuracy data. Eur J Nucl Med Mol Imaging. 2015;42 Suppl 1:S680.
4.
Bakker IL, Fröberg AC, Busstra M, van Leenders GJLH, de Blois E, Schoots I, et al. A novel gallium-68-labelled GRP receptor antagonist, [68Ga]Sarabesin 3, for prostate cancer imaging: first results in therapy naïve primary patients. Eur J Nucl Med Mol Imaging. 2015;42 Suppl 1:S125.
5.
Antunes IF, Dost R, van Waarde A, Dierckx R, Samplonius D, Helfrich W, et al. Synthesis and evaluation of Androgen Receptor radioligand [18F]enzalutamide: comparison with [18F] FDHT. Eur J Nucl Med Mol Imaging. 2015;42 Suppl 1:S260.
6.
Gourni E, Goncalves V, Denat F, Meyer PT, Maecke HR. NODA-GA-PSMA: a versatile probe for SPECT/PET imaging of PSMA-positive tumors. Eur J Nucl Med Mol Imaging. 2015;42 Suppl 1:S174.
7.
Cardinale J, Schäfer M, Benesova M, Bauder-Wüst U, Komljenovic D, Eder M, et al. Radiosyntheses and preclinical evaluation of radiofluorinated PSMA-ligands. Eur J Nucl Med Mol Imaging. 2015;42 Suppl 1:S173.
8.
Boschi S, Lodi F, Cicoria G, Marengo M, Fanti S. One pot Al18F Radiofluorination of GLU-UREA-LYS(AHX)-HBED-CC PSMA ligand. Eur J Nucl Med Mol Imaging. 2015;42 Suppl 1:S303.
9.
Skoura E, Almukhalid OM, Panagiotidis E, Al Harbi M, Kayani I, Michopoulou S, et al. The influence of 68Ga-DOTATATE PET/CT imaging in the management decision of patients with neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2015;42 Suppl 1:S230.
10.
Nicolas GP, Mansi R, Kaul F, Vomstein S, Kaufmann J, Bouterfa H, et al. 68Ga-OPS202/177Lu-OPS201, a high performance theranostic pair of radiolabelled somatostatin antagonists for PET imaging and radionuclide therapy: translational aspects. Eur J Nucl Med Mol Imaging. 2015;42 Suppl 1:S129.
11.
Pouw B, deWit-van der Veen LI, van Duijnhoven F, Rutgers EJT, Valdés Olmos RA, Stokkel MPM, et al. 3D freehand-SPECT navigation for intraoperative radioactive seed localisation using single or multiple 125I seeds in breast-conserving cancer surgery. Eur J Nucl Med Mol Imaging. 2015;42 Suppl 1:S94.
12.
Kleinjan GH, Van den Berg NS, Wit E, Vegt E, Van Leeuwen FWB, Van der Poel HG. Multimodal imaging agents for sentinel node mapping as a means to (re)connect nuclear medicine to advances made in robot assisted surgery. Eur J Nucl Med Mol Imaging. 2015;42 Suppl 1:S128.
13.
Caobelli F, Alongi P, Evangelista L, Rensi M, Castello A, Laghai I, et al. Predictive value of 18F-FDG PET/CT in restaging patients affected by ovarian cancer: a multicenter study. Eur J Nucl Med Mol Imaging. 2015;42 Suppl 1:S126.
14.
Marner L, Nysom K, Sehested A, Borgwardt L, Mathiasen R, Wehner PS, et al. Clinical impact of simultanous 18FET PET/MRI for pediatric CNS-tumors. Eur J Nucl Med Mol Imaging. 2015;42 Suppl 1:S205.
15.
Luo H, Hong H, Shi S, Graves SA, Nickles RJ, Cai W. OP620 PET imaging of c-Met in cancer with 64Cu-labeled hepatocyte growth factor. Eur J Nucl Med Mol Imaging. 2015;42 Suppl 1:S262.
16.
Honarvar H, Westerlund K, Altai M, Sandström M, Orlova A, Tolmachev V, et al. Feasibility of affibody molecule-based PNA-mediated pretargeting. Eur J Nucl Med Mol Imaging. 2015;42 Suppl 1:S101.
17.
Pouget J, Ladjohounlou R, Pichard A, Boudousq V, Paillas S, Le Blay M, et al. Involvement of direct and indirect (bystander) cytotoxic effects in alpha-RITof small volume peritoneal carcinomatosis using 212Pb-labeled mAbs. Eur J Nucl Med Mol Imaging. 2015;42 Suppl 1:S202.
18.
Dalm S, Sieuwerts A, Look M, Melis M, van Deurzen V, Foekens J, et al. Clinical relevance of targeting SSTR2, GRPR and CXCR4 with radioligands for imaging and therapy in breast cancer. Eur J Nucl Med Mol Imaging. 2015;42 Suppl 1:S163.
19.
Kratochwil C, Giesel FL, Afshar-Oromieh A, Benešová M, Mier W, Eder M, et al. First results with Lu-177-PSMA617 in targeted radionuclide therapy of patients with metastatic hormone-refractory prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42 Suppl 1:S130.
20.
Kulkarni HR, Wester HJ, Singh A, Baum RP. Value of Ga-68 PSMA PET/CT for patient selection and follow-up of metastasized prostate cancer patients undergoing peptide radioligand therapy (PRLT) with Lu-177 DOTAGA-PSMA inhibitor. Eur J Nucl Med Mol Imaging. 2015;42 Suppl 1:S175.
21.
Kletting P, Schuchardt C, Kulkarni H, Sayeg M, Wiesalla S, Winter G, et al. Quantifying the effect of peptide amount on the biologically effective dose for therapy using Lu-177 Labeled PSMA ligands. Eur J Nucl Med Mol Imaging. 2015;42 Suppl 1:S160.
22.
Spohn FO, Kunze K, Giesel F, Mier W, Haberkorn U, Kratochwil C. Radionuclide therapy of metastatic melanoma with benzamide derivate I-131-BA100 after patient stratification with F-18-DOPA. Eur J Nucl Med Mol Imaging. 2015;42 Suppl 1:S92.
23.
Prince J, Zonnenberg BA, Nijsen JFW, Smits MLJ, van den Hoven AF, Wessels FJ, et al. Efficacy of radioembolization with holmium-166 microspheres; primary outcome of the phase II HEPAR trial. Eur J Nucl Med Mol Imaging. 2015;42 Suppl 1:S172.
24.
Królicki L, Morgenstern A, Kunikowska J, Koziara H, Królicki B, Jakuciński M, et al. Recurrent glioblastoma multiforme - local alpha emiters targeted therapy with 213Bi-DOTA-substance P. Eur J Nucl Med Mol Imaging. 2015;42 Suppl 1:S84.
25.
Muselaers CHJ, Boers-Sonderen MJ, van Oostenbrugge TJ, Boerman OC, Desar IME, Stillebroer AB, et al. Phase II study of lutetium-177-labeled anti carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2015;42 Suppl 1:S170.
26.
Pryma DA, Jimenez C, Chin B, Olsen JR, Pampaloni MH, Solnes LB, et al. Preliminary dosimetry results from a phase II study evaluating the efficacy and safety of Ultratrace® Iobenguane I 131 in patients with relapsed/refractory malignant pheochromocytoma/paraganglioma. Eur J Nucl Med Mol Imaging. 2015;42 Suppl 1:S15.
27.
Boni G, Mazzarri S, Menconi M, Traino AC, Borsò E, Bernasconi S, et al. Preliminary experience in treating high-risk neuroblastoma using tandem high dose dosimetry-guided 131I-MIBG treatment combined with chemotherapy. Eur J Nucl Med Mol Imaging. 2015;42 Suppl 1:S170.
28.
Herrmann K, Schottelius M, Lapa C, Poschenrieder A, Hänscheid H, Keller U, et al. First-in-man experience of CXCR4-directed endoradiotherapy with 177Lu- and 90Y-labelled pentixather in heavily pretreated multiple myeloma with extensive intra- and extramedullary disease. Eur J Nucl Med Mol Imaging. 2015;42 Suppl 1:S12.
29.
Dahle J, Repetto-Llamazares A, Melhus KB, O’Shea A, Generalov R, Andersen J, et al. Comparison of murine and chimeric version of the anti-CD37 antibody HH1 used for antibody-radionuclide-conjugate (ARC) therapy of Non-Hodgkin Lymphoma. Eur J Nucl Med Mol Imaging. 2015;42 Suppl 1:S418.
30.
Stokke C, Løndalen A, Blakkisrud J, Dahle J, Bach-Gansmo T, Holtedahl J, et al. Tumour-absorbed dose for patients in a phase I study undergoing antibody-radionuclide-conjugate (ARC) therapy with 177Lu-DOTA-HH1. Eur J Nucl Med Mol Imaging. 2015;42 Suppl 1:S14.
31.
Taddei C, Bongarzone S, Haji Dheere A, Gee AD. Carbonylation via conversion of [11C]CO2 into [11C]CO mediated by [11C]Silane derivatives. Eur J Nucl Med Mol Imaging. 2015;42 Suppl 1:S41.
32.
Zischler J, Zlatopolskiy BD, Krapf P, Zarrad F, Urusova EA, Kordys E, et al. Efficient production of PET tracers on a preparative scale viacopper-mediated radiofluorination under “minimalist” conditions. Eur J Nucl Med Mol Imaging. 2015;42 Suppl 1:S42.
33.
Rami-Mark C, Wadsak W, Philippe C, Vraka C, Hoepping A, Hacker M, et al. [11C]Me@HAPTHI - A Novel PET-ligand for the norepinephrine transporter: preclinical evaluation. Eur J Nucl Med Mol Imaging. 2015;42 Suppl 1:S280.
34.
Gargiulo S, Anzillotti S, Coda A, Gramanzini M, Greco A, Panico M, et al. Imaging of brain TSPO expression in a mouse model of amyotrophic lateral sclerosis with [18F]DPA-714 and micro-PET/CT. Eur J Nucl Med Mol Imaging. 2015;42 Suppl 1:S291.
35.
Tóth M, Little P, Arnberg F, Häggkvist J, Mulder J, Varrone A, et al. Longitudinal imaging of acute neuroinflammation with [11C]PBR28 in an ischemic stroke rat model. Eur J Nucl Med Mol Imaging. 2015;42 Suppl 1:S22.
36.
Brendel M, Jaworska A, Probst F, Overhoff F, Carlsen J, Lindner S, et al. PET imaging of tau pathology in two transgenic mouse models using [18F]-THK-5117. Eur J Nucl Med Mol Imaging. 2015;42 Suppl 1:S21.
37.
Zhou X, de Vries E, Ishiwata K, Dierckx R, Nishiyama S, Tsukada H, et al. In vivo evaluation of [11C]preladenant for imaging of adenosine A2A receptors in the conscious monkey. Eur J Nucl Med Mol Imaging. 2015;42 Suppl 1:S19.
38.
Gejl M, Egejord L, Møller A, Hansen SB, Vang K, Rodell A, et al. OP322 GLP-1 analogue liraglutide prevents decline of brain glucose metabolism in Alzheimer’s Disease: randomized, placebo-controlled double-blinded clinical trial. Eur J Nucl Med Mol Imaging. 2015;42 Suppl 1:S132.
39.
Sonni I, Fazio P, Schain M, Halldin C, Svenningsson P, Farde L, et al. Simplified quantification of the dopamine transporter using [18F]FE-PE2I in PD patients and control subjects. Eur J Nucl Med Mol Imaging. 2015;42 Suppl 1:S235.
40.
Pontecorvo M, Grundman M, Dubois B, Nobili F, Sadowsky C, Mcgeehan A, et al. A randomized, controlled, multicenter, internationalstudy of the impact of florbetapir (18F) PETamyloid imaging on patient management and outcome. Eur J Nucl Med Mol Imaging. 2015;42 Suppl 1:S133.
41.
Caobelli F, Thackeray JT, Soffientini A, Bengel FM, Pizzocaro C, Guerra UP. Feasibility of an eighth-time gated myocardial perfusion SPECT functional imaging using IQ-SPECT system. Eur J Nucl Med Mol Imaging. 2015;42 Suppl 1:S229
42.
Liu J, Hasche E, Kilian J, Dixson H, Elison B, Bui C, et al. Clinical utilization of submillisievert stress only myocardial perfusion imaging and concurrent coronary artery calcium score: a single institutional experience of a novel cardiac SPECT camera using cadmium zinc telluride (CZT) semiconductor technology. Eur J Nucl Med Mol Imaging. 2015;42 Suppl 1:S73.
43.
Redgate S, Barber DC, Fenner JW, Al-Mohammad A, Taylor JC, Hanney MB, et al. Correcting for patient motion on a solid state multiple pinhole dedicated cardiac camera. Eur J Nucl Med Mol Imaging. 2015;42 Suppl 1:S48.
44.
Rijnierse MT, Allaart CP, De Haan S, Harms HJ, Huisman MC, Beek AM, et al. Role of myocardial perfusion, sympathetic denervation and scar size in predicting inducibility of ventricular arrhythmia in ischemic cardiomyopathy. Eur J Nucl Med Mol Imaging. 2015;42 Suppl 1:S29.
45.
Kan H, Knol RJJ, Lazarenko SV, Wondergem M, Hoogvorst NJ, van der Zant FM. Occurrence and characterisation of perfusion defects on 13NH3 myocardial PET/CT due to side branch occlusion after ramus descendens anterior stenting. Eur J Nucl Med Mol Imaging. 2015;42 Suppl 1:S78.
46.
Sgard B, Djelbani S, Tordjmann J, Pop G, Nunes H, Valeyre D, et al. Value of FDG-PET/CT and cardiac MR for the diagnosis and therapy monitoring in cardiac sarcoidosis. Eur J Nucl Med Mol Imaging. 2015;42 Suppl 1:S178.
47.
Dellavedova L, Maffioli LS. The prognostic value of baseline 18F-FDG PET/CT in steroid-naïve large-vessel vasculitis: introduction of volume-based parameters. Eur J Nucl Med Mol Imaging. 2015;42 Suppl 1:S522.
48.
Hyafil F, Laitinen I, Schottelius M, Mohring M, Poschenrieder A, Brandl J, et al. Evaluation of the radiotracer [68Ga]pentixafor targeting the CXCR4 receptor with PET-MRI in a rabbit model of atherosclerotic plaques. Eur J Nucl Med Mol Imaging. 2015;42 Suppl 1:S194.
49.
Galli F, Manni I, Piaggio G, Balogh L, Weintraub BD, Skudlinski MW, et al. Radiolabelled superagonist rhTSH analogues TR1401 and TR1402 for in vivo imaging of poorly differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2015;42 Suppl 1:S88.
50.
Aarntzen E, De Jong D, Hermsen R, Drenth J, Boerman O, Oyen W. Tc-99m-CXCL8 SPECT to image disease activity in inflammatory bowel disease. Eur J Nucl Med Mol Imaging. 2015;42 Suppl 1:S44.
51.
Medaer E, Hoffman I, Thimister W. Impact of colonic transit scintigraphy on clinical decision making in severely constipated children. Eur J Nucl Med Mol Imaging. 2015;42 Suppl 1:S182.
52.
Beekman FJ, van der Have F, Goorden MC, Vaissier PEB, van Roosmalen J, During H, et al. G -SPECT-I: a full ring high sensitivity and ultra-fast clinical molecular imaging system with <3mm resolution. Eur J Nucl Med Mol Imaging. 2015;42 Suppl 1:S209.
53.
Segbers M, Haeck JC, Bakker IL, de Swart J, Kovács M, Bernsen MR, et al. Initial experiences with the Mediso nanoSCAN preclinical SPECT/MR. Eur J Nucl Med Mol Imaging. 2015;42 Suppl 1:S86.
54.
Kühnel C, Winkens T, Freesmeyer M. The general idea and the functionality behind real-time handheld emission spot allocator (rthESA) for simultaneous fusion imaging with ultrasound. Eur J Nucl Med Mol Imaging. 2015;42 Suppl 1:S366.
55.
Engberg AME, Hansen AE, Langer SW, Johannesen HH, Langer NH, Nørgaard M, et al. Multiparametric characterization of early tumour response using PET/MR in patients with lung cancer using a voxelwise analysis. Eur J Nucl Med Mol Imaging. 2015;42 Suppl 1:S16.
56.
Eberlein U, Nowak C, Lapa C, Bluemel C, Peper M, Werner RA, et al. Different DNA damage repair rates in blood lymphocytes after peptide receptor radionuclide therapy and radioiodine therapy of thyroid cancer. Eur J Nucl Med Mol Imaging. 2015;42 Suppl 1:S114.
57.
Johnsen B, Fasmer K, Boye K, Rosendahl K, Biermann M, Trovik C, et al. Cumulative radiation dose received by diagnostic imaging during staging and treatment of primarily operable ewing sarcoma in patients diagnosed in Norway 2005–2012. Eur J Nucl Med Mol Imaging. 2015;42 Suppl 1:S271.
Metadata
Title
Highlights lecture EANM 2015: the search for nuclear medicine’s superheroes
Authors
Andreas Buck
Clemens Decristoforo
Publication date
01-09-2016
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 10/2016
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-016-3423-4

Other articles of this Issue 10/2016

European Journal of Nuclear Medicine and Molecular Imaging 10/2016 Go to the issue

Original Article

Ruptured human Achilles tendon has elevated metabolic activity up to 1 year after repair

Original Article

PET/CT comparing 68Ga-DOTATATE and other radiopharmaceuticals and in comparison with CT/MRI for the localization of sporadic metastatic pheochromocytoma and paraganglioma

Editorial

PET/CT is a cost-effective tool against cancer: synergy supersedes singularity

Original Article

Diagnostic accuracy of FDG PET/CT for clinical evaluation at the end of treatment of HL and NHL: a comparison of the Deauville Criteria (DC) and the International Harmonization Project Criteria (IHPC)

Erratum

Erratum to: Development of a nomogram combining clinical staging with 18F-FDG PET/CT image features in non-small-cell lung cancer stage I–III

Review Article

Contribution of 18F-FDG PET in the diagnostic assessment of fever of unknown origin (FUO): a stratification-based meta-analysis